ArticleScientific reports2026
Identification of key genes in the pathogenesis of hepatic ischemia-reperfusion injury based on bioinformatics and experimental verification.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Hepatic ischemia-reperfusion injury (HIRI) is a frequently encountered complication during liver surgical procedures, characterized by ischemia-induced damage and exacerbated inflammatory injury upon reperfusion. The underlying mechanisms remain incompletely understood, and few targeted therapies are currently available. By employing a mouse HIRI model and whole-transcriptome sequencing, we obtained gene expression profiles across different HIRI stages. 115 candidate genes were identified by differential and intersection analyses of the self-sequenced data, which were further prioritized using protein-protein interaction network analysis and machine learning algorithms. Ultimately, three key genes-Adh4, Akr1c14, and Cxcl1-were identified, which were mainly enriched in in pathways such as aerobic respiration, mitochondrial protein containing complex, ribonucleoprotein complex biogenesis. Immune infiltration analysis indicated significant changes in 13 immune cell types, including granulocytes and neutrophils. Construction of a molecular regulatory network highlighted potential regulators such as the long non-coding RNA Socs1, transcription factor NFKB1, and microRNA mmu-let-7b-5p. The key genes were verified at both transcriptional and translational levels with animal model samples. Notably, ladarixin, a non-competitive antagonist of CXCR1/2, exhibited a protective effect against HIRI, suggesting that Cxcl1 may serve as a promising therapeutic target. However, further comprehensive research is necessary to gain deeper insights into the exact mechanisms by which these genes function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.